Roche has launched Tecentriq, a groundbreaking immunotherapy drug for lung cancer that can be administered subcutaneously, reducing the delivery time from hours to just seven minutes. This innovation is expected to significantly enhance the treatment experience for patients, especially given that lung cancer accounts for about 80,000 new diagnoses annually in India. Doctors emphasize that the subcutaneous delivery method not only minimizes discomfort but also improves patient compliance, as it can be administered by trained nurses in local facilities, eliminating the need for complex setups. However, the treatment comes at a high cost, with a Maximum Retail Price of around ₹3.7 lakh (approximately $4,500 USD) per vial, and patients typically require about six cycles. Roche has introduced patient support programs, including the Blue Tree initiative, which aims to alleviate some of the financial burden. Currently, only about 15% of lung cancer patients can afford the treatment without assistance, but this figure increases to 40% with support. The long-term outlook suggests that as demand increases, prices may decrease.